Pellets, Patches, Creams, or Pills: The 2026 BHRT Delivery Method Guide

Compounded hormone pellets promise “set it and forget it” estrogen and testosterone — a single in-office insertion every three to six months, no daily patches or creams. The pitch is everywhere on Instagram and in med-spa lobbies. The evidence behind it is more contested than the marketing lets on.

The American College of Obstetricians and Gynecologists, in its November 2023 Clinical Consensus, advised clinicians not to routinely prescribe compounded bioidentical menopausal hormone therapy — including pellets — when FDA-approved formulations exist. The Menopause Society’s 2022 position statement was similarly cautious, citing reports of supraphysiologic hormone levels, mood changes, hair changes, and unscheduled bleeding in pellet recipients. The FDA-approved transdermal patches, oral micronized progesterone, and vaginal estradiol products that get less attention online have decades of randomized trial data behind them.

Here is the honest version, the one we give our own patients. Some women genuinely do well on pellets. Most do at least as well — at lower cost, with better dose control, and with stronger safety data — on an FDA-approved patch plus oral progesterone. Here is how the five main delivery methods actually compare.

For systemic hormone therapy in perimenopause and menopause, the choices that matter are:

• Transdermal estradiol patch (FDA-approved) — a small adhesive worn on the lower belly or hip, changed once or twice a week.
• Oral micronized progesterone (FDA-approved, brand name Prometrium and generics) — a capsule taken at bedtime, used alongside estrogen if a woman still has a uterus.
• Vaginal estradiol (FDA-approved as cream, tablet, ring) — low-dose, localized, for genitourinary symptoms specifically.
• Compounded estradiol cream or gel — a custom-mixed topical from a compounding pharmacy. Not FDA-approved as a finished product.
• Compounded subcutaneous pellet — a rice-sized cylinder of compressed estradiol (and sometimes testosterone) inserted under the skin of the hip, lasting three to six months. Not FDA-approved.

Two of these — the FDA-approved patch and oral micronized progesterone — are what most major society guidelines recommend as the default for systemic menopause hormone therapy in a woman with a uterus. Vaginal estradiol stands somewhat apart: it treats vaginal dryness, painful sex, and recurrent UTIs locally, and isn’t a substitute for systemic therapy when systemic symptoms are present.

Estrogen swallowed as a pill passes through the liver first, which alters clotting-factor production and is why oral estrogen carries a higher risk of venous thromboembolism (VTE) — blood clots in the legs and lungs — than estrogen absorbed through the skin.

The size of that difference is well-characterized. A 2015 systematic review and meta-analysis in The Journal of Clinical Endocrinology & Metabolism pooled 15 observational studies and found oral estrogen carried a relative risk of VTE of 1.63 (95% CI 1.40–1.90) versus transdermal, and a relative risk of deep vein thrombosis of 2.09. Earlier pooled work put the VTE risk ratio at roughly 1.9 for oral versus 1.0 for transdermal — meaning transdermal estrogen, in observational data, doesn’t appear to raise VTE risk above the background rate. The UK’s NICE menopause guidance, updated in 2024, specifically recommends the transdermal route for women at higher VTE risk, including those with a BMI above 30.

This is the single biggest reason estrogen through the skin — patch, gel, or cream — is preferred over an oral pill for most women starting menopause hormone therapy today. It is not, on its own, a reason to default to pellets: pellets bypass the liver too, but they also bypass the patient’s ability to adjust the dose if something feels off.

The estradiol patch is the most-studied transdermal option. Several FDA-approved products are on the U.S. market — Climara, Vivelle-Dot, Minivelle, Alora, and generic estradiol patches among them — at doses from 0.025 mg to 0.1 mg per day, changed once or twice a week.

The evidence supports predictable serum estradiol levels in the physiologic premenopausal range, lower VTE risk than oral estrogen, effective relief of vasomotor symptoms, and bone protection at standard doses. Because the product is FDA-approved, every patch in the box matches the pharmacokinetic profile used in the trials.

What patches are not great at: staying on through swimming, sweating, and humidity. Skin irritation under the adhesive is the most common complaint, and changing the dose means a new prescription, not a re-titration on the fly.

For women with a uterus, the patch is paired with oral micronized progesterone at bedtime (typically 100 mg continuous or 200 mg cyclic). Micronized progesterone is bioidentical, FDA-approved, and mildly sedating — which is why nighttime dosing is standard. Transdermal estradiol plus oral micronized progesterone is the regimen The Menopause Society’s 2022 Hormone Therapy Position Statement points to as a well-supported default.

If the main symptoms are vaginal dryness, painful sex, urinary urgency, or recurrent UTIs — now grouped as genitourinary syndrome of menopause — vaginal estradiol is the right tool. FDA-approved forms include cream (Estrace, Premarin vaginal), a tablet (Vagifem, Yuvafem, Imvexxy), and a slow-release ring (Estring, Femring).

Vaginal estradiol works locally at very low doses with minimal systemic absorption, and major society guidelines consider it safe for most women — including many breast cancer survivors after individualized review. It is not designed to treat hot flashes, mood, or bone loss. Many women use both: a patch for systemic symptoms, vaginal estradiol for the local ones.

A compounding pharmacy can prepare estradiol into a custom cream, gel, troche, or capsule. Compounding is legal under USP standards 795 and 797, and there are legitimate reasons to choose it: a documented allergy to inactive ingredients in an FDA-approved product, or a dose that isn’t manufactured.

The problem the major guidelines flag is routine use of compounded products as first-line when an FDA-approved equivalent exists. ACOG’s 2023 Clinical Consensus puts it plainly: clinicians should counsel patients that FDA-approved menopausal hormone therapies are recommended over compounded bioidentical menopausal hormone therapy. The 2022 Menopause Society position lists the concerns — minimal regulatory oversight, no batch-level testing for potency and purity, no FDA-required risk label, and no large randomized trials of the specific formulation a given patient receives.

A compounded cream isn’t inherently dangerous, and many women use them without issue. The point is the evidence base supporting an FDA-approved patch is much deeper, and the FDA-approved product usually costs less out of pocket because insurance covers it.

Compounded subcutaneous hormone pellets — also called BHRT pellets — are the delivery method most aggressively marketed in the wellness space and the one major medical societies have flagged most directly.

The marketing case is partly true: pellets deliver continuous hormone exposure for three to six months without daily user effort, and some women report symptom relief they didn’t get on patches or creams. A 2019 observational comparison from a single practice found pellet users reported greater symptom improvement than transdermal users on a menopause symptom scale. Patients who like pellets often like them a lot.

The concerns from the guideline bodies are also real:

• Supraphysiologic levels. Pellets are dosed to last months, so peak serum estradiol (and testosterone, when included) tends to run above the premenopausal physiologic range in the weeks after insertion. The Menopause Society’s 2022 statement flags this directly — hormone levels well above normal female ranges, associated with mood changes, scalp hair thinning, unwanted body hair, acne, and unscheduled bleeding.
• No reversibility. A patch comes off in seconds. A pellet, once inserted, generally cannot be retrieved without minor surgery, and keeps releasing hormone until it dissolves.
• No FDA approval. Every compounded pellet is custom-made; potency and dissolution rate vary batch to batch. There is no large randomized trial of any specific pellet formulation comparable to the trials behind FDA-approved patches.
• Cost and access. Insurance typically does not cover compounded pellet insertion, so patients pay out of pocket every three to six months. The annual total often exceeds an FDA-approved patch with insurance.

None of this means pellets never have a place. It means the default conversation should start with FDA-approved options, and pellets should be a deliberate choice made by an informed patient — with baseline labs, follow-up labs four to six weeks after insertion, and a clear discussion of what cannot be undone if a dose runs high.

A thoughtful BHRT consult starts with what you’re actually trying to treat — vasomotor symptoms, sleep, mood, vaginal dryness, bone density — and works backward to the formulation that fits. For most women in the 10-year window after menopause, that starting point is an FDA-approved transdermal estradiol patch, oral micronized progesterone if a uterus is present, and vaginal estradiol added if local symptoms are part of the picture. That regimen is what the major guidelines support, what most insurance plans cover, and what has the strongest safety data.

Pellets are a reasonable conversation for a smaller group: women who have given the standard regimen a fair trial, want continuous dosing for lifestyle reasons, and accept the trade-offs — out-of-pocket cost, no quick reversibility, and the monitoring needed to keep levels physiologic. That’s a real conversation, not a no. It’s also not where we start on day one for most women.

If you have been pellet-curious because the algorithm has been showing you pellets — or you’ve tried a patch and want to know whether something else might work better — that’s exactly the kind of conversation we have at Naya Wellness. Carolyn Pampalone, MSN, FNP-BC, has spent nearly two decades in women’s health and hormone care and can walk through the trade-offs, order the right baseline labs, and design a plan you can adjust as you go. You can talk it through at our Chatsworth or Santa Barbara clinics, or by telehealth across California.

Two California locations and statewide telehealth — click a card to view details, or call to schedule a consult.